Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and Other Less-Commonly Used Radiotracers
{"title":"Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and Other Less-Commonly Used Radiotracers","authors":"Roya Eisazadeh MD, FEBNM , Malihe Shahbazi-Akbari MD , Seyed Ali Mirshahvalad MD, MPH, FEBNM , Christian Pirich MD, PhD , Mohsen Beheshti MD, FEBNM, FASNC","doi":"10.1053/j.semnuclmed.2024.01.002","DOIUrl":null,"url":null,"abstract":"<div><p>Following the previous part of the narrative review on artificial intelligence (AI) applications in positron emission tomography (PET) using tracers rather than <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]F-FDG), in this part we review the impact of PET-derived radiomics data on the diagnostic performance of other PET radiotracers, <sup>18</sup>F-O-(2-fluoroethyl)-L-tyrosine ([<sup>18</sup>F]F-FET), <sup>18</sup>F-Fluorothymidine ([<sup>18</sup>F]F-FLT) and <sup>11</sup>C-Methionine ([<sup>11</sup>C]C-MET). [<sup>18</sup>F]F-FET-PET, using an artificial amino acid taken up into upregulated tumoral cells, showed potential in lesion detection and tumor characterization, especially with its ability to reflect glioma heterogeneity. [<sup>18</sup>F]F-FET-PET-derived textural features appeared to have the potential to reveal considerable information for accurate delineation for guiding biopsy and treatment, differentiate between low-grade and high-grade glioma and related wild-type genotypes, and distinguish pseudoprogression from true progression. In addition, models built using clinical parameters and [<sup>18</sup>F]F-FET-PET-derived radiomics features showed acceptable results for survival stratification of glioblastoma patients. [<sup>18</sup>F]F-FLT-PET-based characteristics also showed potential in evaluating glioma patients, correlating with Ki-67 and patient prognosis. AI-based PET-volumetry using this radiotracer as a proliferation marker also revealed promising preliminary results in terms of guide-targeting bone marrow-preserving adaptive radiation therapy. Similar to [<sup>18</sup>F]F-FET, the other amino acid tracer which reflects cellular proliferation, [<sup>11</sup>C]C-MET, has also shown acceptable performance in predicting tumor grade, distinguishing brain tumor recurrence from radiation necrosis, and treatment monitoring by PET-derived radiomics models.</p><p>In addition, PET-derived radiomics features of various radiotracers such as [<sup>18</sup>F]F-DOPA, [<sup>18</sup>F]F-FACBC, [<sup>18</sup>F]F-NaF, [<sup>68</sup>Ga]Ga-CXCR-4 and [<sup>18</sup>F]F-FMISO may also provide useful information for tumor characterization and predict of disease outcome.</p><p>In conclusion, AI using tracers beyond [<sup>18</sup>F]F-FDG could improve the diagnostic performance of PET-imaging for specific indications and help clinicians in their daily routine by providing features that are often not detectable by the naked eye.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0001299824000023/pdfft?md5=3c21bb99ce86211ab2191ed6c03b81bd&pid=1-s2.0-S0001299824000023-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299824000023","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Following the previous part of the narrative review on artificial intelligence (AI) applications in positron emission tomography (PET) using tracers rather than 18F-fluorodeoxyglucose ([18F]F-FDG), in this part we review the impact of PET-derived radiomics data on the diagnostic performance of other PET radiotracers, 18F-O-(2-fluoroethyl)-L-tyrosine ([18F]F-FET), 18F-Fluorothymidine ([18F]F-FLT) and 11C-Methionine ([11C]C-MET). [18F]F-FET-PET, using an artificial amino acid taken up into upregulated tumoral cells, showed potential in lesion detection and tumor characterization, especially with its ability to reflect glioma heterogeneity. [18F]F-FET-PET-derived textural features appeared to have the potential to reveal considerable information for accurate delineation for guiding biopsy and treatment, differentiate between low-grade and high-grade glioma and related wild-type genotypes, and distinguish pseudoprogression from true progression. In addition, models built using clinical parameters and [18F]F-FET-PET-derived radiomics features showed acceptable results for survival stratification of glioblastoma patients. [18F]F-FLT-PET-based characteristics also showed potential in evaluating glioma patients, correlating with Ki-67 and patient prognosis. AI-based PET-volumetry using this radiotracer as a proliferation marker also revealed promising preliminary results in terms of guide-targeting bone marrow-preserving adaptive radiation therapy. Similar to [18F]F-FET, the other amino acid tracer which reflects cellular proliferation, [11C]C-MET, has also shown acceptable performance in predicting tumor grade, distinguishing brain tumor recurrence from radiation necrosis, and treatment monitoring by PET-derived radiomics models.
In addition, PET-derived radiomics features of various radiotracers such as [18F]F-DOPA, [18F]F-FACBC, [18F]F-NaF, [68Ga]Ga-CXCR-4 and [18F]F-FMISO may also provide useful information for tumor characterization and predict of disease outcome.
In conclusion, AI using tracers beyond [18F]F-FDG could improve the diagnostic performance of PET-imaging for specific indications and help clinicians in their daily routine by providing features that are often not detectable by the naked eye.
人工智能在肿瘤分子 PET 成像中的应用:[18F]F-FDG示踪剂之外的叙述性综述,第二部分。[18F]F-FLT、[18F]F-FET、[11C]C-MET 及其他不常用的放射性示踪剂。
继上一部分关于人工智能(AI)在正电子发射断层扫描(PET)中的应用的叙述性综述之后,本部分将讨论使用18F-氟脱氧葡萄糖([18F]F-FDG)以外的示踪剂、在本部分中,我们将回顾正电子发射计算机断层成像(PET)放射组学数据对其他正电子发射计算机断层成像放射示踪剂(18F-O-(2-氟乙基)-L-酪氨酸([18F]F-FET)、18F-氟胸苷([18F]F-FLT)和 11C-蛋氨酸([11C]C-MET)诊断性能的影响。[18F]F-FET-PET使用的是一种被上调的肿瘤细胞吸收的人工氨基酸,在病灶检测和肿瘤特征描述方面显示出潜力,尤其是其反映胶质瘤异质性的能力。[18F]F-FET-PET衍生出的纹理特征似乎有可能揭示出大量信息,用于准确划分以指导活检和治疗,区分低级别和高级别胶质瘤及相关的野生型基因型,并区分假性进展和真正的进展。此外,利用临床参数和[18F]F-FET-PET衍生的放射组学特征建立的模型显示,对胶质母细胞瘤患者进行生存分层的结果是可以接受的。基于[18F]F-FLT-PET的特征也显示出评估胶质瘤患者的潜力,与Ki-67和患者预后相关。使用这种放射性示踪剂作为增殖标志物的基于 AI 的正电子发射计算机断层显像也显示,在指导靶向骨髓保留适应性放射治疗方面取得了令人鼓舞的初步成果。与[18F]F-FET类似,另一种反映细胞增殖的氨基酸示踪剂[11C]C-MET在预测肿瘤分级、区分脑肿瘤复发和放射坏死以及通过PET衍生放射组学模型进行治疗监测方面也表现出了可接受的性能。此外,[18F]F-DOPA、[18F]F-FACBC、[18F]F-NaF、[68Ga]Ga-CXCR-4 和 [18F]F-FMISO 等多种放射性同位素的 PET 衍生放射组学特征也可为肿瘤特征描述和疾病预后预测提供有用信息。总之,使用[18F]F-FDG以外的示踪剂进行人工智能可以提高正电子发射计算机断层成像对特定适应症的诊断性能,并通过提供肉眼通常无法检测到的特征来帮助临床医生进行日常工作。
期刊介绍:
Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.